This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Evaluation of Keyo in Children With Epilepsy

Sponsored by Vitaflo International, Ltd

About this trial

Last updated 9 years ago

Study ID

MCT-Keyo-11/12/15-01

Status

Completed

Type

Interventional

Phase

N/A

Placebo

No

Accepting

18-75 Years
3+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 9 years ago

What is this trial about?

To evaluate the tolerance, acceptability and compliance of Keyo in 20 subjects aged 3 years and over, with intractable epilepsy or Glut-1 DS on a KD.

What are the participation requirements?

Yes

Inclusion Criteria

- 3 years and over

- Confirmed diagnosis of intractable epilepsy or Glut-1 DS

- Children must be currently established on a KD for at least 3 months, taken orally

- Written, informed consent by participant/carer